PCM
OBIO icon

PenderFund Capital Management’s Orchestra BioMed OBIO Stock Holding History

PenderFund Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-55,300
Closed -$748K – 130
2022
Q4 		$748K Buy
+55,300
New +$550K 0.22% 62

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFG
SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

PenderFund Capital Management's OBIO Position: Q1 2023 in Review

PenderFund Capital Management sold out of Orchestra BioMed (OBIO) in Q1 2023, closing a stake of 55,300 shares — an estimated $748K sold.

PenderFund Capital Management first reported a position in OBIO in Q4 2022 and held it in 1 quarter. The position peaked at $748K in Q4 2022. 22 funds tracked by Wall St. Rank hold OBIO as of Q1 2023.

  • PenderFund Capital Management reported no remaining Orchestra BioMed position as of Q1 2023 after selling out during the quarter.
  • PenderFund Capital Management sold 55,300 Orchestra BioMed shares in Q1 2023, an estimated $748K.
  • PenderFund Capital Management first reported a position in Orchestra BioMed in Q4 2022 and held it in 1 quarter.
  • PenderFund Capital Management's Orchestra BioMed position peaked at $748K in Q4 2022.
  • 22 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2023.

Based on PenderFund Capital Management's 13F filing for Q1 2023, filed 15 May 2023.